Summary
Johnson & Johnson shows that its psoriasis drug Tremfya can definitely go toe to toe with Novartis' Cosentyx.
Cosentyx was shown to have a rapid onset of action (early treatment period); however, JNJ fared better at the final primary endpoint of PASI 90 at 48 weeks.
Tremfya also proved non-inferiority when compared to Cosentyx in this phase 3 comparison study.
Analysts believes that Tremfya in the psoriasis space could earn up to $1.56 billion in sales by 2022.
Sales for Tremfya are important because JNJ's old psoriasis drug, anti-TNF Remicade, continues to do poorly against biosimilars.
Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today »
Recently, Johnson & Johnson (JNJ) announced positive results from a phase 3 study using Tremfya to treat patients with psoriasis. These positive results reinforce the drugs prospects, and will allow the company to flesh out the rest of its clinical program. The complete data set was presented at the 3rdInflammatory Skin Disease Summit in Vienna between December 12th through 15th. Most importantly, Tremfya was shown to be superior in PASI score against a competing product over a longer period of time.
